Duan Fujiao, Liu Weigang, Fu Xiaoli, Feng Yajing, Dai Liping, Cui Shuli, Yang Zhenxing
Medical Research Office, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Oncotarget. 2017 Sep 11;8(44):77999-78010. doi: 10.18632/oncotarget.20830. eCollection 2017 Sep 29.
The prognostic significance of MicroRNA-148/152 (miR-148/152) family expression in various cancers has been investigated by many studies with inconsistent results. To address this issue, we performed a meta-analysis to clarify this relationship.
Eligible studies were recruited by a systematic literature search and assessed the quality of included studies based on Quality In Prognosis Studies (QUIPS) and Newcastle-Ottawa Scale (NOS). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and disease free survival/progressive free survival/recurrence free survival (DFS/PFS/RFS) were calculated to estimate the effects of miR-148/152 family expression on prognosis.
A final total of 23 articles (26 studies) were considered in evidence synthesis. A significant association was observed between low miR-148a level and poor OS in patients (HR = 1.59, 95% CI: 1.14 - 2.20, = 0.00), especially with digestive tract cancer (DTC) (HR = 1.29, 95% CI: 1.03-1.63, = 0.03), and another significant association was observed between low miR-148b level and poor OS in patients (HR=2.09, 95% CI: 1.70-2.56, = 0.00), especially with (hepatocellular carcinoma) HCC (HR = 1.97, 95% Cl: 1.52-2.56, = 0.00) and non-small cell lung cancer (NSCLC) (HR = 2.29, 95% Cl: 1.64-3.18, = 0.00). The significant correlation between miR-152 and DFS/RFS was found in our research (HR = 3.49, 95% Cl: 1.13-10.08, = 0.03).
Our findings suggest that low miR-148/152 family expression is significantly associated with poor prognosis and may be a feasible prognostic biomarker in some cancers, especially in HCC and NSCLC.
许多研究探讨了微小RNA-148/152（miR-148/152）家族表达在各种癌症中的预后意义，但结果不一致。为解决这一问题，我们进行了一项荟萃分析以阐明这种关系。
通过系统的文献检索纳入符合条件的研究，并根据预后研究质量（QUIPS）和纽卡斯尔-渥太华量表（NOS）评估纳入研究的质量。计算总生存（OS）和无病生存/无进展生存/无复发生存（DFS/PFS/RFS）的合并风险比（HRs）及95%置信区间（CIs），以估计miR-148/152家族表达对预后的影响。
证据综合分析共纳入23篇文章（26项研究）。观察到患者中低miR-148a水平与不良OS之间存在显著关联（HR = 1.59，95% CI：1.14 - 2.20，P = 0.00），尤其是在消化道癌（DTC）中（HR = 1.29，95% CI：1.03 - 1.63，P = 0.03）；还观察到低miR-148b水平与患者不良OS之间存在显著关联（HR = 2.09，95% CI：1.
